Diabetes
Refine Search
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biosimilars
Sanofi said today that it filed a patent infringement suit against US peer Merck & Co on September 16, 2016 in the USA District Court for the District of Delaware. In its suit Sanofi alleges infringement of 10 patents relating to its blockbuster diabetes treatment Lantus (insulin glargine). 19 September 2016
Pharmaceutical
Horizon Pharma is a very active biopharmaceutical business as it is very acquisitive, wrote ‘Value Investor’ on the Seeking Alpha blog. The company just announced another major purchase, Raptor Pharmaceuticals, after it has made numerous acquisitions in previous years. 18 September 2016
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca announced positive results from the Phase III DURATION-8 trial, which demonstrated that its Bydureon (exenatide extended-release) for injectable suspension 2mg once-weekly in combination with Farxiga (dapagliflozin) 10mg once-daily significantly reduced blood sugar as measured by HbA1c, versus the individual medicines alone in patients with type 2 diabetes inadequately controlled on metformin. 17 September 2016
Pharmaceutical
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended eleven medicines for approval at its September meeting. Among these were: 17 September 2016
Pharmaceutical
Novo Nordisk has presented promising data both on a Phase III drug and an existing product at the Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016. 16 September 2016
Pharmaceutical
Merck & Co in partnership with its peer Pfizer announced that a Phase III study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint. 15 September 2016
Pharmaceutical
Sanofi has presented new data suggesting that a fixed-ratio combination of lixisenatide and insulin glargine, known as iGlarLixi, helps more diabetes patients with type 2 diabetes to reach mealtime blood sugar targets than insulin glargine alone. 15 September 2016
Pharmaceutical
The 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) is now taking place in Munich, Germany, and included some notable new data presentations. 13 September 2016
Pharmaceutical
Sanofi and Verily Life Sciences (formerly Google Life Sciences), an Alphabet company, today announced the launch of Onduo, a joint venture created through Sanofi and Verily's diabetes-focused collaboration. 12 September 2016
Pharmaceutical
Shares of Dynavax Technologies were jumping 24.29% to $13.56 on heavy trading volume mid-Tuesday morning as investment bank William Blair said the US Food and Drug Administration’s cancellation of a November 16 Vaccines and Related Biological Products Advisory Committee meeting for the company's hepatitis B vaccine Heplisav is a net positive. 11 September 2016
Pharmaceutical
Lexicon Pharmaceuticals today revealed that the pivotal inTandem1 Phase III clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on a background of optimized insulin. 9 September 2016
Biotechnology
US biotech firm AnTolRx has signed a Series A funding agreement with pharma giant Pfizer, Orion Equity Partners and JDRF, the leading global organization funding type 1 diabetes (T1D) research. 8 September 2016
Pharmaceutical
Novo Nordisk announced on Friday that the US Food and Drug Administration has extended the regulatory review period for IDegLira, the fixed-ratio combination of insulin degludec (Tresiba) and liraglutide (Victoza) in adults with type 2 diabetes. 5 September 2016
Pharmaceutical
Novo Nordisk says that the European Commission has approved the expanded use of Xultophy. 2 September 2016
Pharmaceutical
Danish diabetes giant Novo Nordisk has announced the retirement of its chief executive Lars Rebien Sørensen. 1 September 2016
Pharmaceutical
Takeda Pharmaceutical today announced the launch of a new Access to Medicines (AtM) strategy, aimed at increasing access to its innovative and potentially life-saving medicines for patients with some of the highest unmet medical needs. 26 August 2016
Pharmaceutical
The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022, at a strong compound annual growth rate of 12.7%. 25 August 2016
Pharmaceutical
A new comparison claims that Adlyxin (lixisenatide), a drug from French pharma major Sanofi which gained US Food and Drug Administration (FDA) approval last month for type 2 diabetes, is safer than a top-selling treatment marketed by Novo Nordisk. 22 August 2016
Pharmaceutical
French pharma major Sanofi says it has submitted updated information on the pen delivery device as part of the New Drug Application (NDA) for iGlarLixi. 22 August 2016
Pharmaceutical
As many as 20,000 Australians living with type 2 diabetes will find it easier and cheaper to manage their condition every day thanks to the Turnbull Government subsidizing another A$70 million ($53.8 million) round of new revolutionary medicines that will also help save the lives of women with advanced cervical cancer. 15 August 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze